New medication more potent, longer lasting than morphine

Jan 04, 2011

(PhysOrg.com) -- A little-known morphinelike drug is potentially more potent, longer lasting and less likely to cause constipation than standard morphine, a study led by a Loyola University Health System anesthesiologist has found.

The drug, morphine-6-0-sulfate, has a similar to standard . Dr. Joseph Holtman Jr. and colleagues reported that a study they performed in rats "demonstrated potential clinical advantages of morphine-6-0-sulfate compared to morphine."

Holtman is first author of the study, published in the December 2010 issue of the European Journal of Pharmacology.

Holtman is medical director of Loyola's Specialty Service and a professor in the departments of Anesthesiology and and Therapeutics of Loyola University Chicago Stritch School of Medicine. He directed the study while he was at the University of Kentucky’s College of Medicine. He joined Loyola on March 1, 2010.

Opioids, such as morphine, oxycodone and hydrocodone, are standard drugs for treating moderate to severe pain, including cancer pain. But these drugs can have significant side effects, including constipation, nausea, vomiting, drowsiness, cognitive dysfunction and slowed breathing and heart rates. And while opioids work well for conditions such as back pain and post-operative pain, the drugs are less effective against neuropathic pain, such as tingling, burning or shooting pain.

Constipation is a common side effect of morphine and can be so uncomfortable that some patients limit their use of the drug. Doctors typically do not discharge surgery patients until they have had a bowel movement and this can extend hospital stays.

Holtman and colleagues tested standard morphine and morphine-6-0-sulfate on rats. The animals received the drugs three ways -- by mouth, by IV and by injection into the space surrounding the spinal cord.

The rats underwent several well-established tests to determine their sensitivity to pain. In one such test, researchers focused a very warm light beam on the tail and measured how long it took for the rat to flick the tail.

In this tail-flick test, morphine-6-0-sulfate was 10 times more potent than standard morphine when administered in the space surrounding the spinal cord, five times more potent when administered by IV and two times more potent when given by mouth. Morphine-6-0-sulfate maintained its maximum effect for three hours, compared with 1½ hours for standard morphine. And it took rats 25 days to build tolerance to morphine-6-0-sulfate, compared with 10 days with standard morphine.

Morphine-6-0-sulfate also was more potent than standard morphine for neuropathic and inflammatory pain.

Researchers found that morphine-6-0-sulfate could cause constipation, but only at doses 10 to 20 times higher than the effective doses.

The findings suggest that morphine-6-0-sulfate "may be an interesting potential drug for further study," Holtman and colleagues wrote.

Explore further: Evidence lacking for long-term opioid use in low back pain

Provided by Loyola University

3.5 /5 (6 votes)
add to favorites email to friend print save as pdf

Related Stories

Morphine blocks tumor growth

Jul 28, 2010

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the ...

Morphine kills pain -- not patients

Mar 21, 2007

Many people, including health care workers, believe that morphine is a lethal drug that causes death when used to control pain for a patient who is dying. That is a misconception according to new research published in the ...

Researchers find new target to improve pain management

Sep 07, 2010

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic ...

Recommended for you

Pyridoxine-doxylamine drug safety data lacking

11 hours ago

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

FDA approves new type 2 diabetes drug

Apr 15, 2014

(HealthDay)—Millions of Americans with type 2 diabetes have a new treatment option with the U.S. Food and Drug Administration's approval Tuesday of a once-weekly injectable drug, Tanzeum.

User comments : 4

Adjust slider to filter visible comments by rank

Display comments: newest first

Quantum_Conundrum
2.3 / 5 (3) Jan 04, 2011
...and of course, they'll just charge 10 to 20 times more to administer this drug.
kshultz222_yahoo_com
5 / 5 (1) Jan 04, 2011
The biggest problem is that it will take 10 - 20 years to get it on the market.
ormondotvos
5 / 5 (1) Jan 04, 2011
Well, how hard is it to synthesize?

Big market to constipated chronic pain sufferers ... sell it on the street outside medical cannabis clinics.
wileruilaer
not rated yet Jan 05, 2011
I wonder if addictiveness is also 2-10 times higher. If so, this drug would probably not be very useful for the majority of pain sufferers, but would mostly be used the same way we use the more potent opioids today, in specialized surgical, oncological, neurological and palliative settings where addiction is already considered a secondary problem. In those cases, reduced side effects would be welcome. If, however, this drug also exhibits significantly less addictiveness - this might be a very welcome addition in the arsenal of primary health care pain relief.

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

How kids' brain structures grow as memory develops

Our ability to store memories improves during childhood, associated with structural changes in the hippocampus and its connections with prefrontal and parietal cortices. New research from UC Davis is exploring ...

Ebola virus in Africa outbreak is a new strain

The Ebola virus that has killed scores of people in Guinea this year is a new strain—evidence that the disease did not spread there from outbreaks in some other African nations, scientists report.